Sickle Cell Disease
Conditions
Keywords
sickle cell disease
Brief summary
To evaluate PK and PD responses to L-citrulline given orally for four weeks to patients with sickle cell disease who are otherwise healthy.
Detailed description
Phase 1, single center, open label, multiple-dose study consisting of a screening period followed by four weeks of treatment. At least 12 male and female patients, 10 years of age or older, with sickle cell disease but otherwise healthy, will be enrolled in the study. PK measurements include plasma concentrations of L-citrulline, L-arginine, L-ornithine, and L-proline following the first dose of orally administered L-citrulline and after four weeks of twice daily administration of the drug. PD measurements include intercellular and vascular adhesion molecules (ICAM, VCAM, and E-selectin), surrogate markers of sickle cell disease activity, and PAT, a measurement of vascular function.
Interventions
Sponsors
Angiogenix
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
10 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female, 10 years of age or older on the day of dosing, and generally healthy as determined by medical history, physical examination, and laboratory test values 2. Diagnosis of sickle cell anemia (Hb SS) 3. For female of child-bearing potential, a negative serum pregnancy test and using an adequate method of contraception 4. Has signed and received a copy of the written informed consent form approved by the investigator's Institutional Review Board (IRB), understands the purposes and risks of the study and agrees to follow the restrictions and schedule of procedures as defined by this protocol
Exclusion criteria
1. History of sickle-cell-related pain crisis within two weeks of study 2. Pregnant or breast feeding 3. Transfusion within last 90 days 4. Creatinine \>1.5 X upper limit of normal 5. SGPT \> 2 X upper limit of normal 6. History of allergic reaction to arginine or citrulline product 7. Requires chronic medication other than study drug that cannot be discontinued during the study period 8. Unable to take or tolerate oral medications 9. Unreliable venous access 10. Noncompliant with regular care 11. Participation in an investigational drug or medical device study within previous 30 days 12. In the opinion of the investigator is not a good candidate for participation in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PK and PD responses to L-citrulline | — |
| Endpoints will be determined as change from baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| Assessment of safety and tolerability of L-citrulline, | — |
Countries
United States
Outcome results
None listed